Screener
Nuvation Bio NUVB Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| For the Six Months Ended June 30, | 2026 | 2025 |
|---|---|---|
| Proceeds from exercises of options | 4,409 | 1,844 |
| Net cash provided by financing activities | 170,573 | 193,971 |
| Effect of foreign exchange rate changes on cash and cash equivalents | (510) | 23 |
| Net increase in cash and cash equivalents | 94,518 | 212,247 |
| Cash and cash equivalents, beginning of the period | 164,086 | 35,723 |
| Cash and cash equivalents, end of the period | $258,604 | $247,970 |
| Non-cash operating activities | ||
| Right-of-use asset recognized | $185 | $3,772 |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's net change in cash?
- Nuvation Bio (NUVB) reported net change in cash of $133.21M in Q2 2026.
- How has Nuvation Bio's net change in cash changed year-over-year?
- Nuvation Bio's net change in cash decreased by 33.4% year-over-year, from $199.99M to $133.21M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Nuvation Bio's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude